Not checkedNot checked for notices yet.
Acute reaction after administration of nimotuzumab: a concern
Kamon Chaiyasit, Viroj Wiwanitkit
Journal of Acute Disease · 2014
doi:10.1016/s2221-6189(14)60038-x (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
*Corresponding author: Dr. Kamon Chaiyasit, Vital Life, Bumrungrad Hospital, Bangkok Thailand. Sir, the immunotherapy is the new modality in medical treatment. This kind of treatment has been introduced for using in oncology for a few years and the nimotuzumab is a new immunotype anticancer drug that is useful for management of several cancers[1,2]. Here, the authors would like to share experience on using this drug. As a immunotype drug, the concern is on the adverse effect due to the immunoreaction of the patients. Of overall 6 cases who used this drug in the experience of the author, there is a case with acute reaction after administration of nimotuzumab. The case is a male patient with liver cancer and the reaction occurred within 10 min after receiving of nimotuzumab. The reaction is acute shaking and chill. In fact, this kind of reaction can be seen in any immunotherapy. Nevertheless, there has been no official report on the prevalence of this acute complication of nimotuzumab and this report is the first world report on this topic. Based on this work, the one-sixth rate seems to be very high and should be a concern for the oncologist in using this drug. In fact, a recent report from China also documented for the high rate of adverse effect in using nimotuzumab combining with radiotherapy. In that report, it was quoted that “Grade 3-4 adverse events and toxicities occurred in 50% of the patients[3].” Nevertheless, this is only the preliminary observation and further study to accumulate the information is suggested. Conflict of interest statement
Abstract licence: CC BY-NC-ND
References3
3 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.